Pentraxin 3 in neonates with and without diagnosis of pulmonary hypertension

Farhadi, Roya; Rafiei, Alireza; Hamdamian, Sahar; Zamani, Hasan; Yazdani, Jamshid

doi:10.1016/j.clinbiochem.2016.11.009

Cited by 9 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the mean Pentraxin 3 of the later group was significantly higher than that of the control. This was in agreement with several studies which found that the mean serum pentraxin 3 in neonates with PHT was significantly higher than that of the control and neonates with other CHD [14], [15], [16]. Also, we found that the mean hs-CRP of the PHT neonates was significantly higher than that of the control.…”

Section: Discussionsupporting

confidence: 93%

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

Wakeel¹,

Sabry²,

El-Kassas³

et al. 2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND:Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long pentraxins, which plays an essential role in regulation of cell proliferation and angiogenesis.AIM:This study aims to assess serum pentraxin 3 levels in neonates with pulmonary arterial hypertension and compare them in those who have other congenital heart diseases and healthy neonates. Also, we intended to evaluate serum levels of CRP as a mediator of inflammation in the studied groups.METHODS:The study is a case-control study. Cases were recruited from El Galaa Teaching Hospital, classified into three groups; each group had thirty cases. The first one: cases with pulmonary hypertension (PHT), the second one: cases with congenital heart diseases (CHD) without pulmonary hypertension and the third group included healthy neonates. All participants were subjected to full history taking and full clinical examination. Diagnosis of congenital heart disease and pulmonary hypertension was made according to echocardiographic findings by pediatric cardiologist using echocardiography machine. Laboratory investigations included measurement of serum pentraxin 3, Routine CBC, CRP.RESULTS:This study found that the mean serum pentraxin 3 in PHT neonates was significantly higher than that of the control and CHD neonates (p ≤ 0.001, p = 0.02 respectively). Also, the mean Pentraxin3 of the CHD neonates was significantly higher than that of the control (p = 0.06). Also, the mean CRP of the PHT neonates was significantly higher than that of the control (p = 0.01). Regression analysis showed that Pentraxin3 was the main predictor of PAP (P = 0.01).CONCLUSION:Serum pentraxin 3 is significantly elevated in neonates with pulmonary hypertension, so measurement of pentraxin 3 levels in neonates may be valuable as a predictor for pulmonary hypertension in neonates.

show abstract

Section: Discussionsupporting

confidence: 93%

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

Wakeel¹,

Sabry²,

El-Kassas³

et al. 2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Plasma PTX3 might be a reliable biomarker in the diagnosis of neonatal PAH. 27 VEGF is essential for intraocular neovascular disorders and tumor angiogenesis, and VEGF plasma levels are found to be elevated in PAH patients. 15 In our paper, we demonstrated higher serum levels of VEGF in APE-PAH patients, and, serum VEGF levels were positively correlated with PAP grading in APE-PAH patients, which had a diagnostic power in patients.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic values of serum BNP, PTX3, and VEGF in acute pulmonary embolism complicated by pulmonary artery hypertension and their correlations with severity of pulmonary artery hypertension

Zheng,

Zhang,

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThis paper aimed to unveil the diagnostic values of serum brain natriuretic peptide (BNP), pentraxin 3 (PTX3), and vascular endothelial growth factor (VEGF) in acute pulmonary embolism complicated by pulmonary artery hypertension (APE‐PAH) and their correlations with severity of PAH.MethodsA total of 153 patients with APE were selected for our study and divided into the PAH and Non‐PAH groups according to the measurement of pulmonary artery pressure by echocardiography. Serum BNP levels were measured by chemiluminescence immunoassay, and serum PTX3 and VEGF levels were appraised by ELISA. The predictive values of BNP, PTX3, and VEGF for APE‐PAH were evaluated by applying the receiver operating characteristic (ROC) curve. Spearman test was implemented to correlate BNP, PTX3, and VEGF with the severity of PAH.ResultsHigher serum levels of BNP, PTX3, and VEGF were observed in the PAH group versus the Non‐PAH group (p < .05). ROC curve analysis indicated that BNP, PTX3, and VEGF had acceptable diagnostic value for predicting APE‐PAH. Higher serum levels of BNP, PTX3, and VEGF were witnessed in the moderate and severe PAH groups in contrast to the mild PAH group (p < .05), and the levels of these parameters were elevated in the severe PAH group versus the moderate PAH group (p < .05). Spearman correlation analysis signified that serum BNP (r = 0.377), PTX3 (r = 0.488), and VEGF (r = 0.575) levels were positively correlated with the severity of PAH in APE‐PAH patients.ConclusionSerum BNP, PTX3, and VEGF levels are significantly elevated in APE‐PAH patients. Serum BNP, PTX3, and VEGF levels are of clinical value in the diagnosis of APE‐PAH patients, and serum BNP, PTX3, and VEGF levels are positively correlated with the severity of PAH and can be used as predictors of the severity of PAH.

show abstract

“…Sciacca et al showed that PTX3 was significantly higher at 24 hours of life in late preterms with respiratory failure requiring the use of assisted ventilation and oxygen concentration in the respiratory mixture (FiO 2 >0.8) compared to marginally preterms with respiratory failure treated with continuous positive airway pressure (CPAP) and requiring oxygen concentration of up to 50% (19) . It was also demonstrated that PTX3 may be a useful diagnostic marker for pulmonary hypertension (20) and sepsis in full-term neonates (21) . Battal et al assessed peripheral blood cell count and the levels of PTX3, CRP and procalcitonin (PCT) in 30 1-and 7-day-old neonates with clinical manifestations of infection.…”

Section: Ptx3 In Neonates and Childrenmentioning

confidence: 99%

Pentraxin 3 – possible uses in neonatology and paediatrics

Szymkowiak¹,

Surmiak²,

Baumert³

2020

Pediatr Med Rodz

View full text Add to dashboard Cite

Pentraxin 3 (PTX3) is a multifunctional acute phase protein belonging to the family of long pentraxins, which is synthesised in numerous cells of the body under the influence of proinflammatory factors and locally at the site of inflammation. Under physiological conditions, PTX3 is stored in neutrophil granules, where there is a constant pool of glycoproteins. Increased pentraxin 3 levels in blood serum are observed as early as 1 hour after a damaging stimulus. Elevation of PTX3 serum levels can be used to diagnose fertility disorders in women as well as in pregnancy pathology, women at risk of pre-eclampsia, gestational diabetes, premature rupture of membrane and preterm delivery. The biological function of PTX3 is not fully understood, especially in the population of newborns and children. So far, no reference values for PTX3 levels in newborns and children have been developed. This protein can be used as a marker of pulmonary hypertension in newborns as well as to assess the degree of respiratory failure in premature infants. In older children, it is useful in the assessment of the severity of meningococcal disease and sepsis as well as in the treatment of childhood asthma. There are studies available in which blood levels of PTX3 significantly correlate with the severity of kidney damage in Henoch–Schönlein macular degeneration in children, and the evaluation of this protein in urine is used to detect renal parenchymal destruction after pyelonephritis.

show abstract

Pentraxin 3 in neonates with and without diagnosis of pulmonary hypertension

Cited by 9 publications

References 17 publications

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

Diagnostic values of serum BNP, PTX3, and VEGF in acute pulmonary embolism complicated by pulmonary artery hypertension and their correlations with severity of pulmonary artery hypertension

Pentraxin 3 – possible uses in neonatology and paediatrics

Contact Info

Product

Resources

About